Navigation Links
Imaging Diagnostic Systems Accepts Resignations of Outside Directors
Date:4/23/2008

Company Increases Focus on PMA Study

FORT LAUDERDALE, Fla., April 23 /PRNewswire-FirstCall/ -- Imaging Diagnostic Systems, Inc., (OTC Bulletin Board: IMDS) announced that on April 16, 2008, the Company received and accepted the resignations of its three outside directors Jay Bendis, Patrick Gorman, and Sherman Lazrus. These resignations were tendered to comply with a request by outside funding sources as a condition to such funding. In connection with their resignations, these directors received full vesting on the options for 200,000 shares each, which the Company granted in early 2008.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040412/IMDSLOGO )

Linda B. Grable, a co-founder of IDSI and its former Chairman of the Board and CEO, who retired in April 2004, agreed to come out of retirement and now serves as the Company's Chairman of the Board and interim CEO.

Allan Schwartz, Executive Vice President and CFO stated that, "I am gratified that Linda has come out of retirement to serve IDSI as Chairman of the Board and Interim CEO. Her passion and experience will be a driving force to enable the Company to achieve its financial goals and to complete the PMA filing process."

"As one of the original founders and a shareholder, I have a personal interest as well as a vested interest in IDSI's success," Grable commented. "I felt it was imperative for me to return to the company to help promote goodwill, bring value to the shareholders, and provide the avenue for the company to obtain the resources necessary to continue its operations and complete the PMA process. I am strongly committed to turning the original vision that I shared with my late husband Richard Grable, inventor of the CTLM system, into reality."

On April 18th, 2008 the company entered into a new "Sixth Private Equity Credit Agreement with Charlton Avenue LLC providing a maximum commitment of $15,000,000 for a period of three years from the effective date of registration statement.(for detailed information see April 16th 2008 Form 8-K)

While the Company believes that it will be able to secure the additional funding necessary on commercially reasonable terms and follow the PMA timetable, there can be no assurance that the Company will be able to do so.

About Imaging Diagnostic Systems, Inc.

Imaging Diagnostic Systems, Inc. has developed a revolutionary new imaging device to aid in the detection and management of breast cancer. The CTLM(R) system is a breast imaging system that utilizes patented continuous wave laser technology and computer algorithms to create 3-D images of the breast. The procedure is non-invasive, painless, and does not expose the patient to ionizing radiation or painful breast compression. CT Laser Mammography (CTLM(R)) is designed to be used in conjunction with mammography. It reveals information about blood distribution in the breast and may visualize the process of angiogenesis, which usually accompanies tumor growth.

The FDA has determined that the Company's clinical study is a non- significant risk (NSR) investigational device study under 812.3(m) of the investigational device exemptions (IDE) regulation (21 CFR 812). The company is currently conducting clinical studies to collect the data necessary to support the FDA PMA application. The CTLM system is limited by United States Federal Law to investigational use only in the United States.

For more information, visit our website: http://www.imds.com

As contemplated by the provisions of the Safe Harbor section of the Private Securities Litigation Reform Act of 1995, this news release may contain forward-looking statements pertaining to future, anticipated, or projected plans, performances and developments, as well as other statements relating to future operations. All such forward-looking statements are necessarily only estimates or predictions of future results or events and there can be no assurance that actual results or events will not materially differ from expectations. Further information on potential factors that could affect Imaging Diagnostic Systems, Inc., is included in the Company's filings with the Securities and Exchange Commission. We expressly disclaim any intent or obligation to update any forward-looking statements.

Media Contact:

Deborah O'Brien

(954) 581-9800

obrien@imds.com


'/>"/>
SOURCE Imaging Diagnostic Systems, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Imaging Diagnostic Systems New Laser Breast Imaging Scanner Introduced in Malaysia
2. Largest Asian Cancer Hospital to Evaluate New CT Laser Breast Imaging System
3. Imaging Diagnostic Systems Generates Cash From Building Sale
4. Imaging quantum entanglement
5. Glycominds Joins Biomolecular Photonic (BMP) Consortium to Develop New Molecular Imaging Technique
6. Elbit Medical Imaging Ltd. Announces Definitive Agreements for a Large Scale Luxury Mixed Use Project in Bangalore, India
7. Elbit Medical Imaging Ltd. Announces that Plaza Centers Has Entered into a Joint Venture Partnership to Develop Residential and Office Projects in Romania
8. Elbit Medical Imaging Ltd. Announces Results of Its Annual General Meeting
9. Imaging Diagnostic Systems Expands Key Patent Coverage
10. Imaging Diagnostic Systems Exhibits CT Laser Breast Imaging Results at Major Italian Multidisciplinary Breast Cancer Meeting
11. New Optical Breast Cancer Imaging Technology Garners Cover Story in National Radiology Magazine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... 2017 Scientists propose in Nature ... in Gaucher and maybe other lysosomal storage diseases as ... than current therapies. An international research team ... which also included investigators from the University of Lübeck ... Feb. 22. The study was conducted in mouse models ...
(Date:2/22/2017)... ... February 22, 2017 , ... LabRoots , ... from around the world, is pleased to announce the 2nd annual Precision Medicine ... This premier, online-only conference focused on the development and advancements in precision medicine. ...
(Date:2/22/2017)... MOINES, Iowa , Feb. 22, 2017 Origin (Origin ... agricultural biotechnology trait and seed provider, and Arcadia ... -based company that develops and commercializes agricultural productivity traits and nutritional ... a key corn biotechnology product developed in China ... of global regulatory trials. ...
(Date:2/22/2017)... ... February 22, 2017 , ... Pharma and biotech ... as European director. Operating from Pennside’s Zurich headquarters, Pennside Partners, GmbH, Mr. Perkins ... Pennside after more than a decade with leading market research firm, GfK. He ...
Breaking Biology Technology:
(Date:2/13/2017)... Feb. 13, 2017  RSA Conference -- RSA, a ... is designed to enhance fraud detection and investigation ... the RSA Fraud & Risk Intelligence Suite. The ... leverage additional insights from internal and external sources ... protect their customers from targeted cybercrime attacks. ...
(Date:2/8/2017)... Feb. 7, 2017  Aware, Inc. (NASDAQ: AWRE ... reported financial results for its quarter and year ended December ... of 2016 was $3.9 million compared to $6.9 million in ... quarter of 2016 was $0.6 million compared to $2.6 million ... fourth quarter of 2016 was $0.5 million, or $0.02 per ...
(Date:2/7/2017)... Zimmer Biomet Holdings, Inc. (NYSE and SIX: ... at the LEERINK Partners 6th Annual Global Healthcare Conference ... February 15, 2017 at 10 a.m. Eastern Time. ... be accessed at http://wsw.com/webcast/leerink28/zbh .  The webcast will ... Biomet,s Investor Relations website at http://investor.zimmerbiomet.com . ...
Breaking Biology News(10 mins):